<DOC>
	<DOC>NCT01732458</DOC>
	<brief_summary>The purpose of this study is to determine the appropriate dosing regimen of aprepitant for the prevention of post-operative nausea and vomiting in pediatric participants birth to 17 years.</brief_summary>
	<brief_title>A Study to Evaluate Aprepitant for the Prevention of Post Operative Nausea and Vomiting in Children (MK-0869-219)</brief_title>
	<detailed_description />
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Postoperative Nausea and Vomiting</mesh_term>
	<mesh_term>Aprepitant</mesh_term>
	<mesh_term>Fosaprepitant</mesh_term>
	<mesh_term>Ondansetron</mesh_term>
	<criteria>Participant enrolled at birth should be at least 37 weeks gestation and â‰¥3 kg of weight Scheduled to receive general anesthesia AND must have at least one of the following risk factors for postoperative nausea and vomiting (PONV) in addition to receiving general anesthesia: 1. scheduled to have a surgery with an associated risk of PONV: tonsillectomy, adenoidectomy, strabismus surgery, dental surgery, hydrocelectomy, orchidopexy or herniorraphy; OR 2. scheduled to have an operative procedure associated with PONV: intraoperative opioid use or anticipated opioid administration within the first 24 hours following surgery. Emergency surgery for a lifethreatening condition Scheduled to receive propofol for maintenance of anesthesia (Note: propofol is permitted for induction of anesthesia). Expected to receive opioid antagonists (e.g., naloxone, naltrexone) or benzodiazepine antagonists (e.g., flumazenil) Scheduled to undergo cardiac or neurosurgery Vomiting caused by any organic etiology (such as gastric outlet obstruction or small bowel obstruction) Vomiting within 24 hours prior to surgery Nasogastric or oral gastric tube intra or postoperatively for suctioning gastric contents Active infection (e.g., pneumonia), congestive heart failure, bradyarrythmia, any uncontrolled disease (e.g., diabetic ketoacidosis, gastrointestinal obstruction) except for malignancy, or a history of any illness which in the opinion of the investigator, might confound the results of the study or pose unwarranted risk to the participant Use of any illicit drugs, including marijuana or has current evidence of alcohol abuse</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>